AbbVie highlights Phase 2 APEX Part B data for zumilokibart in atopic dermatitis
AbbVie highlighted positive results from the Phase 2 APEX Part B study of zumilokibart in moderate to severe atopic dermatitis, presented as a late breaker at EADV 2026.